
éå ±ïŒãã¡ã€ã¶ãŒç€Ÿã®mRNAãããèç€ã粟åãè¡æ¶²ã®88%以äžããããŠã¯ã¯ãã³æªæ¥çš®ã®åŠå©Šã®50%ã§çºèŠããã
ããã®çäœå ååžç ç©¶ã§ã¯ããã¡ã€ã¶ãŒã® mRNA ãèå ããã³çæ®çµç¹ã«æµžéããäœå ã«é·æéæ®çããæåºããããšããæç¢ºãªèšŒæ ã瀺ãããŠããŸãã
Nicolas Hulscher, MPH
Dec 04, 2025
ãã³ã©ã¹ã»ãã«ã·ã£ãŒïŒå ¬è¡è¡çåŠä¿®å£«ïŒ
é·å¹Žã«ããããäžè¬ã®äººã ã¯åçŽãªèª¬æãèããããŠãããmRNAã¯ãè ã®äžã«çãŸãããæ°æéã§åè§£ãããè¡æµã«å ¥ãããšããèç€ãééããããšããçæ®åšç³»ã«å°éããããšãããããŠæåºããããä»äººã«ç§»ã£ããããããšã¯æ±ºããŠãªãããšãããã®ã ããããã䞻匵ã¯ãããã«ãããé·æçãªçäœå ååžç ç©¶ãäžåºŠãè¡ãããŠããªãã«ãããããããæ¿åºæ©é¢ããã¡ã¯ããã§ãã«ãŒãå ±éæ©é¢ãå»çæ©é¢ã«ãã£ãŠå»¶ã ãšç¹°ãè¿ãããŠããã
Annals of Case Reportsèªã«æ²èŒãããæ°ããªæ»èªæžã¿ç ç©¶ãããã®è¡æ¶²ãèç€ã粟液ã«ããããã¡ã€ã¶ãŒã»ãã€ãªã³ããã¯ç€Ÿè£œã¡ãã»ã³ãžã£ãŒRNA COVID-19ã¯ã¯ãã³ã®æ€åºãã¯ããã®ç©èªã«çµæ¢ç¬Šãæã€ãã®ã§ãããã®ç ç©¶ãæåã«å ±ããã®ã¯ãXã®VaccineMoleã§ãã
ããŒã»ã€ã©ã³å€§åŠãšã€ã¹ã©ãšã«ã®è€æ°ã®å»çã»ã³ã¿ãŒã®ç ç©¶è ãã¯ã以åã®ç ç©¶ã§äœ¿çšãããæšæºçãªqPCRãããã¯ããã«æåºŠãšç¹ç°æ§ã«åªããæ¹æ³ã§ãããµã³ã¬ãŒé åè§£æãšçµã¿åããããã¹ãPCRã䜿çšããŠãåŠå©Š22åãç·æ§ç²ŸåæäŸè 4åïŒ8ãµã³ãã«ïŒãããã³ãã®ä»æäºº8åãå«ã34åã®åå è ã®äººäœçµç¹äžã®ãã¡ã€ã¶ãŒmRNAãæ€æ»ããã
圌ãã®èª¿æ»çµæã¯éåžžã«ææ ®ãã¹ããã®ã§ããéå»100æ¥ä»¥å ã«ã¯ã¯ãã³æ¥çš®ãåããåŠå©Šã®88%ã§ãè¡æ¶²ãšèç€çµç¹ã®äž¡æ¹ã§ãã¡ã€ã¶ãŒç€Ÿã®mRNAãæ€åºãããŸãããç·æ§ç²ŸåæäŸè ã®ãã¡ã粟åãç£çãã人ã®100%ã§ç²Ÿå现èå ã«ã¯ã¯ãã³mRNAãæ€åºããã50%ã§ã¯ã¯ã¯ãã³æ¥çš®åŸé·æéçµéãã粟液äžã«ãmRNAãæ€åºãããŸããã
ããã«æžå¿µãããã®ã¯ãæ€æ»ãåããã¯ã¯ãã³æªæ¥çš®å¥³æ§ã®50ïŒ ãããã¡ã€ã¶ãŒã®mRNAãæ€åºãããããšã ãèç€ãšè¡æ¶²ã®äž¡æ¹ã§2人ãè¡æ¶²ã®ã¿ã§1人ããã®çµæã¯ç§åŠçã«æåºã®çŸå®ãçŽèŠããããã®ã ããåœå±ã¯ãããæåºãšããŠåŠå®ããŠããã
æãé©ãã¹ãããšã¯ã泚å°åŸ200æ¥ä»¥äžçµéããŠãã50%ã®è¢«éšè ã§mRNAããŸã ååšããŠããããšã§ãã
ããã¯ãæ³šå°æ¶²ããæ°æé以å ãã«åè§£ããã®ã§ã¯ãªããäœå ã«æ®çããŠåŸªç°ãã人éã®çæ®çµç¹ãèå çµç¹ã«èç©ãããšããããããŸã§ã§æãæç¢ºãªèšŒæ ã§ãã
ãã®åœ±é¿ã¯ç倧ã§ãã

æ¹æ³ïŒä»ã®ç ç©¶ã倱æããã®ã«ããªããã®ç ç©¶ãæåããã®ã
ãã®è«æã®æãåªããç¹ã®äžã€ã¯ããã®æ¹æ³è«ã§ãã以åã®ç ç©¶ã§ã¯ã¯ã¯ãã³ã®mRNAãæ€åºã§ããªãã£ãçç±ã«ã€ããŠãèè ãã¯æç¢ºãªèª¬æãããŠããŸãã圌ãã¯qPCRã䜿çšããŠããŸããããqPCRã§ã¯æ³šå°åŸæ°ã¶æçµéãã埮éRNAãæ€åºããæåºŠãäžè¶³ããŠããŸãããæ°ããªç ç©¶ã§ã¯ã代ããã«æåºŠãšç¹ç°æ§ãåçã«åäžããã2段éå¢å¹ æ³ã§ãããã¹ãããPCRãšãå¢å¹ ãããé åãæåéãèªã¿åãããã¡ã€ã¶ãŒã®ã³ã³ã¹ãã©ã¯ããšäžèŽããããšã確èªãããµã³ã¬ãŒã·ãŒã±ã³ã·ã³ã°ãæ¡çšããŸãããéœæ§çµæã¯ãç¬ç«ãã4åã®ãã¯ãã«ã«ãªããŒãã®ãã¡å°ãªããšã3ååºçŸããå Žåã«ã®ã¿æå¹ãšå€æãããããã¯ã°ã©ãŠã³ããã€ãºãå¶çºçãªã³ã³ã¿ãããŒã·ã§ã³ãçµæã«åœ±é¿ãäžããå¯èœæ§ãããã«äœæžããŸããã
ãã®ã¢ãããŒãã¯ããã³ãããã¯äžã«ãCOVIDçäŸãã®èšºæã«äœ¿çšãããPCRæ€æ»ãšã¯æ ¹æ¬çã«ç°ãªããŸãããããã®æ€æ»ã¯ãéåžžã«é«ããµã€ã¯ã«éŸå€ïŒå€ãã®å Žå35ïœ45ãµã€ã¯ã«ïŒã§å®è¡ãããã·ã³ã°ã«ã¹ãããqPCRã«äŸåããŠãããããã¯ã°ã©ãŠã³ããã€ãºã埮éã³ã³ã¿ãããŒã·ã§ã³ããããŠç¡å®³ãªRNAæçã«ãã£ãŠåœéœæ§ãçããå¯èœæ§ããããŸãããäžæ¹ãä»åã®æ°ããç ç©¶ã§äœ¿çšãããæ¹æ³ã§ã¯ããã©ã€ããŒçµåãšå¢å¹ ã2åæåãããè€æ°ã®å埩ã«ãããåçŸæ§ã確èªãããã®åŸãç£ç©ã®åäžæ§ã確èªããããã®ç¬ç«ããã·ãŒã±ã³ã·ã³ã°ç¢ºèªãå¿ èŠã§ãã
èšãæããã°ãCOVID蚺æPCRã¯ãŠã€ã«ã¹RNAã®ããããæçãæ€åºããéœæ§ããšã©ãã«ä»ãã§ãããããã®ç ç©¶ã®ãã¹ãPCRãã©ã¹é åè§£æã§ã¯ãæåããšã«æ€èšŒããããã¡ã€ã¶ãŒmRNAé åã®æ£ç¢ºãªãã®ããæ€åºã§ããªãã
ããã¯ãç ç©¶è ãã¡ãããã€ãºããæ€åºããã®ã§ã¯ãªããååã¬ãã«ã§ç¢ºèªãããçã®ã¯ã¯ãã³mRNAãæ€åºããããšãæå³ããŸããããã¯ããã®åé¡ã«å¯ŸãããããŸã§ã§æã決å®çãªã¢ãããŒãã§ãã
èç€ã§ã¯ã¯ãã³mRNAãæ€åº
åºç£åŸ100æ¥ä»¥å ã«ã¯ã¯ãã³æ¥çš®ãåãã女æ§ã®88%ã§ãè¡æ¶²ãšèç€ã®äž¡æ¹ã§mRNAãæ€åºå¯èœã§ããã230 ïœ251æ¥çµéåŸããäžéšã®èç€ã§ã¯ã¯ã¯ãã³RNAãäŸç¶ãšããŠæ€åºãããŠããŸããã
ããã¯ãmRNA ã¯ãèç€ã«å°éããªãããšäž»åŒµãããã¹ãŠã®å ¬åŒå£°æãšçã£åããççŸããŠããŸãã
粟åãšç²Ÿæ¶²äžã«mRNAãæ€åºããã
ã¯ã¯ãã³æ¥çš®ãåãã4人ã®ç·æ§ã®ãã¡ãæ€æ»ãåããã®ã¯ïŒ
3 人ãçåå¯èœãªç²Ÿåãçæãããã® 100% ã®ç²Ÿå现èã«ãã¡ã€ã¶ãŒã® mRNA ãå«ãŸããŠããŸããã
2 åã§ã¯ç²ŸæŒ¿äžã« mRNA ãæ€åºã§ããŸããã
168æ¥åã«ã¯ã¯ãã³æ¥çš®ãåããããç·æ§ã®ç²Ÿåã«ã¯ããŸã mRNAãååšããŠããã
ãã®ããšã¯ãç·æ§ã®çæ®èœåãçæ®çŽ°èãžã®æé²ããããŠææã®å¯èœæ§ã«ã€ããŠé倧ãªçåãæèµ·ããŸãã
é·æçãªæç¶æ§
è¡æ¶²ãšèç€çµç¹å šäœïŒ
ã¯ã¯ãã³æ¥çš®åŸ200æ¥ä»¥äžçµéããŠãæ€æ»ãåãã人ã®åæ°ã§ãäŸç¶ãšããŠãã¡ã€ã¶ãŒã®mRNAãæ€åºãããŠããã
ããã¯ãã¡ã€ã¶ãŒç€ŸãèŠå¶åœå±ãå ¬è¡è¡çåœå±ã䞻匵ããŠããããšãã¯ããã«è¶ ãããã®ã ã
ã¯ã¯ãã³æªæ¥çš®ã®åŠå©ŠããmRNAãæ€åºããã
ããããæãè¡æçãªçºèŠã¯æ¬¡ã®éãã§ãã
ã¯ã¯ãã³æ¥çš®ãåããŠããªãåŠå©Šã®50ïŒ ãããã¡ã€ã¶ãŒã®mRNAãæ€åºãããŸããã
ã¯ã¯ãã³æ¥çš®ãåããŠããªãåŠå©Š2åã®è¡æ¶²ãšèç€ã®äž¡æ¹ã«ãã¡ã€ã¶ãŒã®mRNAãå«ãŸããŠããã
3人ç®ã®ã¯ã¯ãã³æªæ¥çš®ã®å¥³æ§ã§ã¯ãè¡æ¶²äžã«mRNAã®ã¿ãååšããã
èè ãã¯ã¯ã£ãããšããè¿°ã¹ãŠãããããã®RNAã®åºæã¯ãŸã 調æ»ãããŠããªããã
ããã¯ãmRNAã¯ã¯ãã³ã®æåºã«é¢ããæåã®çŽæ¥çãªèšŒæ ã§ãããšæãããŸãã
çµè«
ãããã®çµæã¯æ¥µããŠéèŠãªæå³ãæã£ãŠããŸããmRNAã¯æ³šå°éšäœã«çãŸãããæ¥éã«åè§£ãããããšããªããèç€ã«å°éããçæ®åšå®ã«äŸµå ¥ããããšã確èªããã®ã§ãã
ããã«ãããéç¯€ãªæå®³äºè±¡ã®é å»¶ã®èåŸã«ããçç©åŠçã¡ã«ããºã ã蚌æããããŸãäžä»£ãè¶ ããæå®³äºè±¡ïŒã¯ã¯ãã³æ¥çš®ãåããæ¯èŠªããçãŸããèµ€ã¡ãããæ°å¹ŽåŸã§ãé«ãéå°æ»äº¡çã瀺ãçç±ïŒã説æãããŸãã
éå ±ïŒCDCã®å°å æ»äº¡èšé²ã¯ãéå£mRNAã¯ã¯ãã³æ¥çš®ã«ããæ·±å»ãªäžä»£ãè¶ ãã害ã瀺ããŠãã
ãã³ã©ã¹ã»ãã«ã·ã£ãŒãMPHã8æ22æ¥

ãã³ã©ã¹ã»ãã«ã·ã£ãŒïŒå ¬è¡è¡çåŠä¿®å£«ïŒ
ãããŠãããããæžå¿µãè¶ ããŠãã¯ã¯ãã³æªæ¥çš®ã®éœæ§åå¿ã¯ããŠã€ã«ã¹ã®æåºãå®éã«èµ·ãã£ãŠããã®ã§ã¯ãªãããšããç念ãçããããŠããã
çµè«ãšããŠããã®ç ç©¶ã¯æ¬¡ã®ããšã瀺ããŠããŸãã
é·æçãªæç¶æ§
å šèº«ååž
çæ®åšç³»ãžã®æé²
èç€ãžã®æé²
ã¯ã¯ãã³æªæ¥çš®è ãžã®æåºã®å¯èœæ§
ããã«ãããçŽã¡ã«åžå Žããæ€éããèåœã®ä»®å®ã«åºã¥ããŠéå€§ãªæå®³ãäžããããšã«ã€ããŠåœæ°ã«è¬çœªããå¿ èŠãããã
æ¯é±èšŒæ ãèç©ãããã«ã€ãããããã®è£œåãåžå Žã«æ®ãããšã§çããæ³ç圱é¿ã¯ãŸããŸãå³ãããªããŸãã
ãã³ã©ã¹ã»ãã«ã·ã£ãŒãMPH
ãã«ããŒè²¡å£ã®ç«åŠè ããã³è²¡å£ç®¡çè
ç§ãã¡ã®äœ¿åœããµããŒãããŠãã ãã: mcculloughfnd.org
ãããªãã³ã³ãã³ãã«ã€ããŠã¯ãMcCullough FoundationãšX (æ§ Twitter)ã®ç§ã®å人ã¢ã«ãŠã³ãã®äž¡æ¹ããã©ããŒããããšãæ€èšããŠãã ããã